This trial is evaluating whether Vincristine Sulfate will improve 1 primary outcome and 10 secondary outcomes in patients with Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma. Measurement will happen over the course of Up to 6 cycles (each cycle is 21 days in length).
This trial requires 24 total participants across 1 different treatment group
This trial involves a single treatment. Vincristine Sulfate is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"This article describes lymphomas, including small non-Hodgkin lymphoma, MALT lymphoma, Mantle cell lymphoma, and chronic lymphocytic leukemia. Chronic lymphocytic leukemia may be caused by a faulty immune system. The causes of lymphoma, b-cell are not yet clearly defined.\n" - Anonymous Online Contributor
"About 30,000 US adults develop lymphoma each year. This is a similar incidence to that seen in Western Europe, with no evidence of an international increase in incidence for the disease." - Anonymous Online Contributor
"Symptoms of lymphoma, b-cell are frequently a poor quality of life. The most common symptoms are bone pain, persistent or progressive systemic symptoms which can cause the patients to lose their appetite, swollen lymph nodes, shortness of breath or a weight loss. Lymphoma, b-cell affects about 3-4 new cases in Canadian every year\n" - Anonymous Online Contributor
"There are more than 1,100 clinical trials enrolling patients for lymphoma therapy. Many of studies are evaluating novel agents or combinations regimens that are either proven to be more effective than standard agents or have a better toxicity profile. Because clinical trials vary, the outcome can be different depending on how you are selected. Please see Power, or withPower.com." - Anonymous Online Contributor
"Lymphoma is treated with chemotherapy, depending on the stage of the disease. The most common stage of disease treated is early B-cell lymphoma with B-cell chronic lymphocytic leukemia being treated the most with chemotherapy. Immunotherapy and targeted therapies are becoming more common, especially in early stage disease. Overall five year survival rates from lymphoma are improving with treatment. This is primarily achieved from the development of more effective chemotherapy regimens and the increased use of new drugs and targeted therapies. Chemotherapy also has an effect on remission rates as does targeted therapy." - Anonymous Online Contributor
"Chronic lymphoproliferative disorders compose >1% of all diagnoses in the US. Lymphoma is also a leading cause of death in most parts of the world. This article provides a review of the clinical features, diagnostic and pathological features, treatment options and prognosis for these disorders." - Anonymous Online Contributor
"These data indicate that lymphoma patients, particularly non-Hodgkin's lymphoma, who are younger than 65 years and have a poorer baseline performance status are potential candidates for clinical trials of the FDA-approved agents. This group also has the greatest potential to improve clinical trial outcomes, both for patients and health care systems." - Anonymous Online Contributor
"In the past, the five-year survival rate for patients with lymphoma and the b-cell subtypes was the same (0.5%). In the present, with the advent of rituximab, a monoclonal antibody against B-cell, that has been shown to be effective for aggressive aggressive lymphomas (MALT/NOS and mantle cell/sessile cell lymphomas), the five-year survival rate is considerably increased. This is based on a recent report." - Anonymous Online Contributor
"We hypothesize that lymphoma in AIDS is due to Epstein-Barr virus infection. Further, this virus is likely transmitted sexually and is not a natural part of human immunity. In an attempt to reduce transmission, HIV-positive individuals should abstain from sexual contact, and condoms may be used with care; these practices should be introduced as early as possible. Because the time interval between onset of HIV infection and development of lymphoma in that individual is highly variable, prophylactic chemotherapy directed toward HIV infection is not recommended." - Anonymous Online Contributor
"B-cell lymphoma is still evolving and the incidence seems to be increasing, however the duration for lymphoma to develop is still shorter than expected. Some clinical trials (in particular CHOP) were less effective than expected even though they had been done for 30 years." - Anonymous Online Contributor
"Results from a recent clinical trial do not support the hypothesis that B-NHL families share an increased susceptibility for some B-NHL subtypes. To our knowledge, this is the first large-scale family-based evaluation of family history of B-NHL." - Anonymous Online Contributor
"[The mechanism of action of cyclophosphamide on lymphomas is to prevent the abnormal proliferation of B-cells. This does not appear to be directly through a cytotoxic effect by cytotoxic chemotherapy. The mechanism appears to be inhibition of pre B-cell differentiation.]" - Anonymous Online Contributor